February 2021 | Vol
Total Page:16
File Type:pdf, Size:1020Kb
THE AMERICAN CHAMBER OF COMMERCE IN TAIPEI IN OF COMMERCE THE AMERICAN CHAMBER February 2021 | Vol. 51 | Issue 2 TAIWAN BUSINESS TOPICS TAIWAN February 2021 | Vol. 51 | Issue 2 Vol. 2021 | February 中 華 郵 政 北 台 字 第 5000 號 執 照 登 記 為 雜 誌 交 寄 Issue Sponsor 2_2020_Cover.indd 1 2021/1/31 11:10 PM MESSAGE FROM BAYER Bayer: Transforming Healthcare through Collaborations and Stefan Oelrich, Member of the Board of Management and Breakthrough Innovation President, Pharmaceuticals Division, Bayer inding effective solutions to the world’s health issues to treatment, empowering patients to make informed, healthy requires novel, holistic approaches and collaborative decisions and take a more active role in their own healthcare. F ingenuity. Healthcare companies must therefore One Drop’s existing diabetes management approach has been increasingly shift their focus to the research and development expanded through its collaboration with Bayer into a holistic of medical technologies, biopharmaceuticals, and innovative digital therapeutics platform. This technology offers a digital, therapies to treat conditions and diseases that are difficult or smart form of integrated care that learns from vast amounts of nearly impossible to tackle using traditional medicines. data and puts the focus on individual patients, not their disease. Such a reality is well understood by Bayer AG. The German Through this and other adaptive technologies, Oelrich said multinational pharmaceutical and life sciences company recently in the Q&A session, Bayer and its collaborators were working held its Virtual Pharma Media Day, where it shared with media toward “making medicines just an accessory to the overall care of professionals around the world the exciting progress it has patients.” made over the past year. The event, which was translated into Finishing the discussion regarding Bayer’s recent progress were 11 different languages, showcased some of Bayer’s investments medical doctor So-Young Kim and Oliver Martin Fischer, principal in external innovation through an unprecedented number of scientist of the company’s Reproductive Health Research team, collaboration agreements and acquisitions – 25 in total in 2020. who both updated the audience about some of the medicines Bayer specialists also outlined some of the assets in its robust currently in Bayer’s mid-stage pharmaceuticals pipeline. Kim, development pipeline. who heads Bayer’s thrombosis and vascular diseases department, To kick off the event, Emile Nuwaysir, CEO and president of discussed the company’s new class of anti-coagulation medicines, BlueRock Therapeutics, and Sheila Mikhail, co-founder and CEO which involve Factor XI (FXI) inhibitors. Based on the company’s of Asklepios BioPharmaceutical (AskBio), introduced a few of research, these drugs could be a promising means of preventing the Bayer’s most recent strides in the area of cell and gene therapy. formation of blood clots and, in effect, of thrombosis. BlueRock, a wholly owned subsidiary of Bayer, is involved in the Fischer introduced Bayer’s P2X3 multi-indication program. development of stem cell treatments to restore lost motor function P2X3 antagonists have been identified for endometriosis, a in patients with Parkinson’s Disease, as well as other degenerative clinical condition affecting 10% of reproductive-age women conditions. AskBio’s AAV-based gene therapy, meanwhile, has that can cause severe chronic pain, as well as other conditions shown promise in treating a range of conditions, including associated with pain and neurogenic hypersensitivity that can Duchenne muscular dystrophy (DMD), and as a therapeutic for affect patients’ quality of life. Bayer’s advances in this area could late-stage heart failure. potentially offer such patients a new treatment approach and Fielding questions from the audience, Stefan Oelrich, a relief, allowing them to start getting back to their normal lives. member of the Bayer AG Board of Management and President of As the presentations and discussions that took place during its Pharmaceuticals Division, said that the company’s acquisitions the Virtual Pharma Media Day clearly indicated, Bayer is of BlueRock and AskBio was just part of its strategy to transform working collaboratively on a comprehensive set of breakthrough the pharma business. treatments. By making tangible progress in the areas of cell and “Our company is at the forefront of the wave of innovation gene therapy and digital health, as well as building and expanding in cell and gene therapy as well as digital health,” Oelrich said. on its impressive development portfolio, Bayer continues to show “We are driving this transformation and growing our promising its strong commitment to transforming patient health. development portfolio together with our partners.” Next to address Bayer’s evolving approach to digital healthcare was Jeff Dachis, founder and CEO of Informed Data Systems, Inc. (One Drop), with whom Bayer has joined forces to develop digital products across multiple therapeutic areas. Dachis related his personal experience being diagnosed with Diabetes Mellitus, saying that his treatment reflected the current medical system’s view of patients with chronic conditions as “discrete silos of medical interventions.” Dachis hopes to change that perception and transform the current care paradigm. He argues for a personalized approach TAIWAN BUSINESS TOPICS • FEBRUARY 2021 3 Bayer advertorial.indd 3 2021/2/1 3:26 PM CONTENTS NEWS AND VIEWS 7 Editorial FEBRUARY 2021 VOLUME 51, NUMBER 2 It’s Time to Drop the “Greater 一一○年二月號 China” Terminology 該讓「大中華區」一詞走入歷史 Publisher 發行人 8 Taiwan Briefs Leo Seewald 李豪 Senior Advisor 資深顧問 By Austin Babb and Jason Wu Don Shapiro 沙蕩 Senior Editor 資深編輯 14 Issues Jeremy Olivier 歐嘉仁 Art Director/ 美術主任/ 6 President’s View Defining Labor Relationships Production Coordinator 後製統籌 定義勞動關係 Katia Chen 陳國梅 A Bullish Start to the Year of the Ox Cover Designer 封面設計 By Leo Seewald By Jeremy Olivier Grace Yang 楊慈安 Manager, Publications Sales & Marketing 廣告行銷經理 Caroline Lee 李佳紋 COVER SECTION Translation 翻譯 Kevin Chen, Yichun Chen, Andrew Wang 歡迎產業回台投資 陳又銘, 陳宜君, 王先棠 Welcoming Industry Back Ashore American Chamber of Commerce in Taiwan 16 Amid a Changing World 129 MinSheng East Road, Section 3, 7F, Suite 706, Taipei 10596, Taiwan Economy, Taiwanese P.O. Box 17-277, Taipei, 10419 Taiwan Tel: 2718-8226 Fax: 2718-8182 Manufacturers Return e-mail: [email protected] website: http://www.amcham.com.tw Home 名稱:台灣美國商會工商雜誌 Taiwan has capitalized on 發行所:台灣美國商會 臺北市10596民生東路三段129號七樓706室 the U.S.-China trade dispute 電話: 傳真: 2718-8226 2718-8182 and superb pandemic control 22 For Taiwan’s Chipmakers, Taiwan Business Topics is a publication of the American to revitalize its position as a Chamber of Commerce in Taiwan. Contents are Navigating U.S.-China independent of and do not necessarily reflect the views of the Officers, Board of Governors, Supervisors or members. technology hub. © Copyright 2021 by the American Chamber of Commerce Rivalry Requires Finesse in Taiwan. All rights reserved. Permission to reprint original By Matthew Fulco material must be requested in writing from AmCham. Reliance on China has never Production done in-house, Printing by Farn Mei Printing Co., Ltd. been riskier for Taiwan's 登記字號:台誌第一零九六九號 印刷所:帆美印刷股份有限公司 semiconductor sector. Industry 經銷商:台灣英文雜誌社 台北市108台北市萬華區長沙街二段66號 giants like TSMC are now 發行日期:中華民國一一○年二月 中華郵政北台字第5000號執照登記為雜誌交寄 investing to increase production ISSN 1818-1961 capacity in the U.S. as means of threading the needle on the Chairperson: CW Chin Vice Chairpersons: Fupei Wang, Timothy Shields American tech dispute with Secretary: Daniel Tseng Treasurer: Angela Yu China. By Matthew Fulco 2020-2021 Governors: C.W. Chin, Brian Sung, Timothy Shields, Fupei Wang, Roger Yee, Angela Yu. 2021-2022 Governors: BACKGROUNDER TAIWAN BUSINESS Justin Chin, Cynthia Chyn, Paulus Mok, Terry Tsao, Daniel Tseng. 28 Taiwan Reaches Out to 2021 Supervisors: Max Chen, Shelley Chia, Seraphim Ma International Media and COMMITTEES: NGOs Agro-Chemical/ Melody Wang; Asset Management/ Eric Lin, Angela Yang, Derek Yung; Banking/ Paulus A more hostile environment for Mok; Capital Markets/ Mandy Huang, Eric Jai, C.P. Liu; Chemical Manufacturers/ Charles Liang, Michael journalists and NGOs in China Wong; Cosmetics/ Abigail Lin; Defense/ Manohar and Hong Kong could make Thyagaraj, Roger Yee; Digital Economy/ Max Chen, Renee Chou, Tai Chi Chuan; Energy/ Richard Freer, Taiwan an ideal location to open Randy Tsai; Human Resources/ Christine Chen, Carmen Law, David Tsai; Infrastructure/ Wayne regional bureaus and offices. 47 Pandemic Affects a Chin, Paul Lee; Insurance/ KT Lim, Mandy Shih, Linda Tsou; Intellectual Property & Licensing/ Jason By Dinah Gardner Multitude of Industries in Chen, Peter Dernbach, Vincent Shih; Marketing & Distribution/ (tba); Medical Devices/ Louis Ko, Jeffrey Taiwan Wang; Pharmaceutical/ Justin Chin, Cellina Yeh, Shuhei Sekiguchi; Private Equity/ Echo Yeh; Public How have other, less well- Health/ Joyce Lee, Pongo Peng, Tim Shields; Retail/ Ceasar Chen, Mark Chen, Peggy Liao; Sustainable reported-on industries coped Development Goals/ Kenny Jeng, Lume Liao, with the changes brought on by Cosmas Lu, Fupei Wang; Tax/ Heidi Liu, Cheli Liaw; Technology/ Cynthia Chyn, Stella Lai, Angela Yu; this global pandemic? Insiders Telecommunications & Media/ Thomas Ee, David Shin, Joanne Tsai; Transportation & Logistics/ (tba); say that digital transformation Travel & Tourism/ Gina Tsai, Jason Yeh, Fiona Yuan. and flexibility